Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study

被引：0
|
作者：
Oaknin, Ana [1 ]
Pothuri, Bhavana [2 ,3 ]
Gilbert, Lucy [4 ]
Sabatier, Renaud [5 ]
Ghamande, Sharad [6 ]
Gravina, Adriano [7 ]
Calvo, Emiliano [8 ]
Banerjee, Susana [9 ,10 ]
Mangan, Niamh [11 ]
Miller, Rowan E. [12 ]
Pikiel, Joanna [13 ]
Mirza, Mansoor R. [14 ]
Duan, Tao [15 ]
Zildjian, Sybil [16 ]
Zografos, Eleftherios [17 ]
Veneris, Jennifer [16 ]
Tinker, Anna V. [18 ]
机构：
[1] Hosp Univ Vall dHebron, Gynaecol Canc Programme, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[2] NYU Langone Hlth, Gynecol Oncol Grp GOG, New York, NY USA
[3] NYU Langone Hlth, Dept Obstet Gynecol, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[4] McGill Univ, Div Gynecol Oncol, Hlth Ctr, Montreal, PQ, Canada
[5] Aix Marseille Univ, Dept Med Oncol, Marseille, France
[6] Augusta Univ, Dept Obstet & Gynecol, Georgia Canc Ctr, Augusta, GA USA
[7] Ist Nazl Tumouri Fdn G Pascale, Clin Trial Unit, Naples, Italy
[8] Ctr Integral Oncol Clara Campal, START Madrid CIOCC, Madrid, Spain
[9] Royal Marsden NHS Fdn Trust, London, England
[10] Inst Canc Res, London, England
[11] GSK, Melbourne, Australia
[12] UCL, St Bartholomews Hosp London, London, England
[13] Reg Ctr Oncol, Dept Chemotherapy, Gdansk, Poland
[14] Rigshosp, Copenhagen Univ Hosp, Nord Soc Gynaecol Oncol Clin Trial Unit, Dept Oncol, Copenhagen, Denmark
[15] GSK, Pennington, NJ USA
[16] GSK, Waltham, MA USA
[17] GSK, London, England
[18] Univ British Columbia, Dept Med, British Columbia Canc, Vancouver Ctr, Vancouver, BC, Canada
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
218
引用
收藏
页码：133 / 134
页数：2
相关论文
共 50 条
  • [31] Interim analysis of the immune-related endpoints of the mismatch repair deficient (dMMR) and proficient (MMRp) endometrial cancer cohorts from the GARNET study
    Oaknin, Ana
    Gilbert, Lucy
    Tinker, Anna
    Sabatier, Renaud
    Boni, Valentina
    O'Malley, David
    Ghamande, Sharad
    Duska, Linda
    Ghatage, Prafull
    Guo, Wei
    Im, Ellie
    Pothuri, Bhavana
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S12 - S13
  • [32] Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair-deficient (dMMR) colorectal cancer (CRC).
    Salem, Mohamed E.
    Andre, Thierry
    El-Refai, Sherif Mohamed
    Kopetz, Scott
    Tabernero, Josep
    Sinicrope, Frank A.
    Tie, Jeanne
    George, Thomas J.
    VanCutsem, Eric
    Mauer, Elizabeth
    Lonardi, Sara
    Overman, Michael J.
    Foureau, David
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] SYSTEMATIC AND STRUCTURED REVIEWS OF THE DISEASE BURDEN IN PATIENTS WITH MICROSATELLITE INSTABILITY HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) COLORECTAL CANCER (CRC)
    Amonkar, M.
    Chase, M.
    Takyar, J.
    Sharma, S.
    VALUE IN HEALTH, 2021, 24 : S24 - S24
  • [34] Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC)
    Andre, Thierry
    Sposetti, Caterina
    Gumus, Mahmut
    Ahn, Joong Bae
    Wyrwicz, Lucjan
    Kwiatkowski, Mariusz
    Kim, Jong Gwang
    Yalcin, Suayib
    Sendur, Mehmet A. N.
    Odeleye-Ajakaye, Amos
    Leconte, Pierre
    Fogelman, David R.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201
    Ciombor, K. K.
    Hong, S.
    Eng, C.
    Yao, X.
    You, N.
    Das, P.
    Chakravarthy, A.
    O'Dwyer, P. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S104 - S104
  • [36] An unusual case of microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) diffuse large B-cell lymphoma revealed by targeted gene sequencing
    Han, Bogyeong
    Kim, Sehui
    Koh, Jiwon
    Bae, Jeong Mo
    Yun, Hongseok
    Jeon, Yoon Kyung
    JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2022, 56 (02) : 92 - 96
  • [37] The efficacy and safety of neoadjuvant immunotherapy in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) localized and oligometastatic colon cancer: Data from the real world.
    Chakrabarti, Sakti
    Parish, Marie
    Peterson, Carrie
    Ludwig, Kirk A.
    Sriram, Deepika
    Ruggeri, Antony
    Tolay, Sameer
    Selfridge, Jennifer Eva
    Bajor, David L.
    Mohamed, Amr
    Mahipal, Amit
    Shreenivas, Aditya V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 105 - 105
  • [38] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis Michel
    Garcia-Carbonero, Rocio
    Alcaide, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna C.
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David R.
    Marinello, Patricia
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Patient-reported outcomes (PROs) in patients (pts) with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
    Valabrega, G.
    Powell, M. A.
    Hietanen, S.
    Miller, E. M.
    Novak, Z.
    Holloway, R.
    Denschlag, D.
    Myers, T.
    Thijs, A. M.
    Pennington, K.
    Gilbert, L.
    Fleming, E.
    Copeland, L.
    Gogoi, R.
    Podzielinski, I.
    Cloven, N.
    Meyers, O.
    Garside, J.
    Mirza, M. R.
    Black, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S513 - S514
  • [40] Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158
    O'Malley, D.
    Bariani, G. M.
    Cassier, P. A.
    Marabelle, A.
    Hansen, A. R.
    Acosta, A. De Jesus
    Miller, W. H., Jr.
    Safra, T.
    Italiano, A.
    Mileshkin, L.
    Xu, L.
    Jin, F.
    Norwood, K.
    Maio, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S730 - S731
12345